LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Gefitinib | 0.04 | uM | LJP6 | 1 | N12 | 72 | hr | 868 | 3985 | 3429 | 1.1619 | 1.1573 |
MDA-MB-231 | Gefitinib | 0.04 | uM | LJP6 | 2 | N12 | 72 | hr | 868 | 4155 | 3652 | 1.1377 | 1.1285 |
MDA-MB-231 | Gefitinib | 0.04 | uM | LJP6 | 3 | N12 | 72 | hr | 868 | 4060 | 3587 | 1.1318 | 1.1247 |
MDA-MB-231 | Gefitinib | 0.12 | uM | LJP6 | 1 | N11 | 72 | hr | 868 | 3634 | 3429 | 1.0595 | 1.0592 |
MDA-MB-231 | Gefitinib | 0.12 | uM | LJP6 | 2 | N11 | 72 | hr | 868 | 4003 | 3652 | 1.0961 | 1.0905 |
MDA-MB-231 | Gefitinib | 0.12 | uM | LJP6 | 3 | N11 | 72 | hr | 868 | 4165 | 3587 | 1.1610 | 1.1514 |
MDA-MB-231 | Gefitinib | 0.37 | uM | LJP6 | 1 | N10 | 72 | hr | 868 | 3516 | 3429 | 1.0251 | 1.0252 |
MDA-MB-231 | Gefitinib | 0.37 | uM | LJP6 | 2 | N10 | 72 | hr | 868 | 3790 | 3652 | 1.0378 | 1.0361 |
MDA-MB-231 | Gefitinib | 0.37 | uM | LJP6 | 3 | N10 | 72 | hr | 868 | 3699 | 3587 | 1.0311 | 1.0302 |
MDA-MB-231 | Gefitinib | 1.11 | uM | LJP6 | 1 | N09 | 72 | hr | 868 | 3614 | 3429 | 1.0537 | 1.0535 |
MDA-MB-231 | Gefitinib | 1.11 | uM | LJP6 | 2 | N09 | 72 | hr | 868 | 3769 | 3652 | 1.0320 | 1.0307 |
MDA-MB-231 | Gefitinib | 1.11 | uM | LJP6 | 3 | N09 | 72 | hr | 868 | 3990 | 3587 | 1.1123 | 1.1067 |
MDA-MB-231 | Gefitinib | 3.33 | uM | LJP6 | 1 | N08 | 72 | hr | 868 | 3614 | 3429 | 1.0537 | 1.0535 |
MDA-MB-231 | Gefitinib | 3.33 | uM | LJP6 | 2 | N08 | 72 | hr | 868 | 3948 | 3652 | 1.0811 | 1.0766 |
MDA-MB-231 | Gefitinib | 3.33 | uM | LJP6 | 3 | N08 | 72 | hr | 868 | 3982 | 3587 | 1.1100 | 1.1046 |
MDA-MB-231 | Gefitinib | 10 | uM | LJP6 | 1 | N07 | 72 | hr | 868 | 3036 | 3429 | 0.8852 | 0.8807 |
MDA-MB-231 | Gefitinib | 10 | uM | LJP6 | 2 | N07 | 72 | hr | 868 | 3294 | 3652 | 0.9020 | 0.9029 |
MDA-MB-231 | Gefitinib | 10 | uM | LJP6 | 3 | N07 | 72 | hr | 868 | 3123 | 3587 | 0.8706 | 0.8691 |
MDA-MB-231 | Nilotinib | 0.04 | uM | LJP5 | 1 | N18 | 72 | hr | 868 | 2890 | 3286 | 0.8794 | 0.8706 |
MDA-MB-231 | Nilotinib | 0.04 | uM | LJP5 | 2 | N18 | 72 | hr | 868 | 3201 | 3505 | 0.9132 | 0.9118 |
MDA-MB-231 | Nilotinib | 0.04 | uM | LJP5 | 3 | N18 | 72 | hr | 868 | 3201 | 3440 | 0.9305 | 0.9287 |
MDA-MB-231 | Nilotinib | 0.12 | uM | LJP5 | 1 | N17 | 72 | hr | 868 | 2580 | 3286 | 0.7851 | 0.7632 |
MDA-MB-231 | Nilotinib | 0.12 | uM | LJP5 | 2 | N17 | 72 | hr | 868 | 2806 | 3505 | 0.8005 | 0.7907 |
MDA-MB-231 | Nilotinib | 0.12 | uM | LJP5 | 3 | N17 | 72 | hr | 868 | 2971 | 3440 | 0.8636 | 0.8577 |
MDA-MB-231 | Nilotinib | 0.37 | uM | LJP5 | 1 | N16 | 72 | hr | 868 | 2433 | 3286 | 0.7404 | 0.7102 |